Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 8
Submit an article Journal homepage
186
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting

Reyhan Yılmaz1 Cerrahpaşa Faculty of Medicine, Istanbul University–Cerrahpaşa, 34303, Istanbul, Turkey
&
Ahmet Emre Eşkazan2 Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University–Cerrahpaşa, 34303, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9568-0894
ORCID Icon
Pages 545-547 | Received 03 Feb 2023, Accepted 23 Feb 2023, Published online: 11 Apr 2023

References

  • Minciacchi VR , KumarR, KrauseDS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells10(1), 117 (2021).
  • Tiribelli M , EşkazanAE. Tyrosine kinase inhibitor sequencing in patients with chronic myeloid leukemia. Oncol. Ther.7(2), 95–100 (2019).
  • Özgür Yurttaş N , EşkazanAE. Novel therapeutic approaches in chronic myeloid leukemia. Leuk. Res.91, 106337 (2020).
  • Malik S , HassanS, EşkazanAE. Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Rev. Hematol.14(11), 975–978 (2021).
  • İbiş B , TiribelliM, EşkazanAE. Asciminib as a new option in the treatment of chronic myeloid leukemia. Future Oncol.17(36), 5003–5005 (2021).
  • Hughes TP , MauroMJ, CortesJEet al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N. Engl. J. Med.381(24), 2315–2326 (2019).
  • Réa D , MauroMJ, BoquimpaniCet al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood138(21), 2031–2041 (2021).
  • Hochhaus A , RéaD, BoquimpaniCet al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia doi: 10.1038/s41375-023-01829-9 (2023) ( Epub ahead of print).
  • Cortes JE , HochhausA, TakahashiNet al. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. doi: 10.2217/fon-2022-0923 (2022) ( Epub ahead of print).
  • Hochhaus A , SausseleS, MahonFXet al. ASC4START: a phase IIIb, open-label, randomized study of tolerability and efficacy of asciminib versus nilotinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Blood140(Suppl. 1), S6787–S6788 [ Abstract] (2022).
  • Cortes J , LangF, KimDWet al. Combination therapy using asciminib plus imatinib (IMA) in patients (PTS) with chronic myeloid leukemia (CML): results from a phase 1 study. HemaSphere.3(Suppl. 1), 397 (2019).
  • Mauro MJ , KimDW, CortesJet al. Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (PTS) with chronic myeloid leukemia (CML): results from a phase 1 study. HemaSphere3(Suppl. 1), S398 (2019).
  • Yeung DT , ShanmuganathanN, ReynoldsJet al. Early and deep molecular responses achieved with frontline asciminib in chronic phase CML – interim results from ALLG CML13 Ascend-CML. Blood140(Suppl. 1), S192–S194 (2022).
  • Cortes JE , HughesT, GeisslerJet al. Efficacy and safety results from ASC4MORE, a randomized study of asciminib (ASC) add-on to imatinib (IMA), continued IMA, or switch to nilotinib (NIL) in patients (Pts) with chronic-phase chronic myeloid leukemia (CML-CP) not achieving deep molecular responses (DMRs) with ≥1 year of IMA. Blood140(Suppl. 1), S195–S197 (2022).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.